GSD Devonian Health Group Inc.

TSXV · CA · Healthcare · Biotechnology · groupedevonian.com

8.000CAD-2.44%Mkt Cap: 16.20M $P/E: —3d ago

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botani…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap16.20M USD

Enterprise Value15.78M USD

Revenue (TTM)2.18M USD

Gross Profit6.23M USD

Net Income (TTM)-4.38M USD

Revenue/Share1.11 CAD

Last Price8.000 CAD

Fiscal Year EndJul 2025

MR QuarterApr 2026

Employees8

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-3.66

EV/Revenue7.23

P/S7.43

P/B3.19

EPS (TTM)-2.13

EPS (Forward)—

52W Range

0.190053% of range15.00

52W High15.00 CAD

52W Low0.1900 CAD

Profitability

Gross Margin36.28%

Oper. Margin-1096.23%

EBITDA Margin-197.67%

Profit Margin-25.49%

ROE-65.80%

ROA-37.98%

Growth

Revenue Growth-97.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-908.71K USD

CapEx (TTM)12.64K USD

FCF Margin-319.51%

FCF Yield-43.02%

Net Debt-421.95K USD

Net Debt/EBITDA0.10

Balance Sheet

Debt/Equity0.01

Current Ratio1.00

Quick Ratio0.78

Book Value/Sh2.51 CAD

Cash/Share0.26 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay DateMay 19, 2017

Splits

Last Split1:60

Split DateJan 22, 2026

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.2.78M

Float2.11M

Insiders12.04%

Institutions0.00%

Short Interest

Short Ratio0.1d

Short % Out.0.01%

Shares Short256

Short (prev mo.)57

Technical

SMA 509.005 (-11.2%)

SMA 20010.48 (-23.7%)

Beta1.24

S&P 52W Chg14.58%

Avg Vol (30d)2.03K

Avg Vol (10d)1.74K

Technical Indicators

RSI (14)41.3

MACD-0.1606

MACD Signal-0.1004

MACD Hist.-0.0602

BB Upper9.801 CAD

BB Middle8.702 CAD

BB Lower7.603 CAD

BB Width25.27%

ATR (14)0.4575 CAD

Vol Ratio (20d)5.50x